http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#Head http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#assertion http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#provenance http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#pubinfo http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#assertion http://purl.obolibrary.org/obo/DOID_3382 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3382 http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08871 http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#association http://www.w3.org/2000/01/rdf-schema#label halaven is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting 1 1 unresectable or metastatic liposarcoma who have received a prior anthracycline containing regimen 1 2 halaven is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting see clinical studies 14 1 halaven is indicated for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline containing regimen see clinical studies 14 2 http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08871 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#provenance http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#pubinfo http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#sig http://purl.org/nanopub/x/hasSignature fpDcMJVxsxOhyck2Gn2YtkCYcNXgPZLlK+ROcj9jJ6znrJPxouYij+1DhAM+a2TGsnmcXPdE+ngTUHY0tBHrqyPi3lRvX+Ko0RbMIsv33F6ZMuC4zmyPlmseP92VT/oeE9b3tQXMVnnywR7jntpKXQhL/xi626E5yEnnQnypb/0= http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc http://purl.org/dc/terms/created 2021-06-12T12:33:50.206+02:00 http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAd951JsHkg4_4jOI_vRodPjHZ9_Ud_06lK1Zb8cgTRSc https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs